13
Participants
Start Date
September 30, 2008
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2013
ISF35
Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
University of California, San Diego Moores Cancer Center, San Diego
Lead Sponsor
The Leukemia and Lymphoma Society
OTHER
University of California, San Diego
OTHER
Memgen, LLC
INDUSTRY